Iron dextran
Brand names: CosmoFer
Iron dextran is a parenteral iron preparation used to treat iron-deficiency anaemia when oral iron is ineffective, not tolerated or unsuitable.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It provides a complex of iron with dextran that is taken up by the reticuloendothelial system, releasing iron for incorporation into haemoglobin and replenishing body iron stores.
Prescribing in practice
- Serious hypersensitivity and anaphylactic reactions can occur, so it must be given where resuscitation facilities are available with monitoring during and after administration.
- Parenteral iron should not be used in the first trimester of pregnancy and is contraindicated in iron overload or non-iron-deficiency anaemia.
- Avoid extravasation, which can cause persistent skin staining at the injection site.
Monitoring
Observe the patient closely for hypersensitivity during and after each dose, and monitor haemoglobin and iron indices to guide replacement.
Counselling the patient
- Tell staff immediately if you feel unwell, dizzy, breathless or develop a rash during the infusion.
- Some delayed flu-like symptoms or joint aches can occur and usually settle.
- You will be observed for a period after the dose as a safety precaution.
Evidence & guidelines
The MHRA advises that all intravenous iron carries a risk of serious hypersensitivity and should be administered with resuscitation facilities available.
Reference: MHRA Drug Safety Update; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO